A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3 Enrolling by invitation 835 enrolled MoonLake Immunotherapeutics AG

NaSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.

Timeline

Start: 2025-06-27
Primary completion: 2028-06-13
Completion: 2028-06-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	M1095	Protein / enzyme biologic	120 mg	Subcutaneous

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Summary

Timeline

Drugs

Indications